Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study

REVELATION BIOSCIENCES, INC.

2026-Q1 EPS reported -$2.71

Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.
Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.
FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.
Received $6.7M net proceeds from January 2026 warrant inducement.
Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.